AIM:DNL

Stock Analysis Report

Executive Summary

Diurnal Group plc operates as a specialty pharma company.

Snowflake

Fundamentals

Adequate balance sheet with limited growth.

Share Price & News

How has Diurnal Group's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

9.1%

DNL

0.1%

GB Biotechs

1.1%

GB Market


1 Year Return

-29.4%

DNL

26.7%

GB Biotechs

2.7%

GB Market

Return vs Industry: DNL underperformed the UK Biotechs industry which returned 26.7% over the past year.

Return vs Market: DNL underperformed the UK Market which returned 2.7% over the past year.


Shareholder returns

DNLIndustryMarket
7 Day9.1%0.1%1.1%
30 Day-1.6%2.9%-1.7%
90 Day3.4%2.4%-2.7%
1 Year-29.4%-29.4%27.7%26.7%7.8%2.7%
3 Year-78.3%-78.3%12.3%10.3%19.3%4.7%
5 Yearn/a55.7%52.0%38.0%8.1%

Price Volatility Vs. Market

How volatile is Diurnal Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Diurnal Group undervalued compared to its fair value and its price relative to the market?

2.32x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate DNL's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate DNL's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: DNL is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: DNL is unprofitable, so we can't compare its PE Ratio to the UK market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate DNL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: DNL is overvalued based on its PB Ratio (2.3x) compared to the GB Biotechs industry average (2.3x).


Next Steps

Future Growth

How is Diurnal Group forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

-3.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: DNL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: DNL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: DNL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: DNL's revenue (53.2% per year) is forecast to grow faster than the UK market (3.8% per year).

High Growth Revenue: DNL's revenue (53.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if DNL's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Diurnal Group performed over the past 5 years?

-31.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: DNL is unprofitable, and losses have increased over the past 5 years at a rate of -31.3% per year.

Accelerating Growth: Unable to compare DNL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DNL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Return on Equity

High ROE: DNL has a negative Return on Equity (-112.28%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: DNL is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: DNL is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Diurnal Group's financial position?


Financial Position Analysis

Short Term Liabilities: DNL's short term assets (£13.4M) exceeds its short term liabilities (£2.5M)

Long Term Liabilities: DNL's short term assets (13.4M) exceeds its long term liabilities (16.0K)


Debt to Equity History and Analysis

Debt Level: DNL is debt free.

Reducing Debt: DNL has no debt compared to 5 years ago when its debt to equity ratio was 411.5%.


Balance Sheet

Inventory Level: DNL has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if DNL's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: DNL has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: DNL has less than a year of cash runway if free cash flow continues to reduce at historical rates of -31.2% each year


Next Steps

Dividend

What is Diurnal Group's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.0%markettop25%5.4%industryaverage0.8%forecastin3Years0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate DNL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate DNL's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if DNL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DNL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DNL's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

What is the CEO of Diurnal Group's salary, the management and board of directors tenure and is there insider trading?

3.8yrs

Average board tenure


CEO

Martin Whitaker 0

0yrs

Tenure

UK£353,000

Compensation

Dr. Martin Whitaker, BSc, Ph.D., serves as the Chief Executive Officer and Executive Director of Diurnal Group Plc since December 1, 2015. Dr. Whitaker serves as an Operations Director of Critical Pharmace ...


CEO Compensation Analysis

Compensation vs. Market: Martin's total compensation ($USD443.99K) is about average for companies of similar size in the UK market ($USD314.44K).

Compensation vs Earnings: Martin's compensation has increased whilst the company is unprofitable.


Board Age and Tenure

3.8yrs

Average Tenure

56.5yo

Average Age

Experienced Board: DNL's board of directors are considered experienced (3.8 years average tenure).


Insider Trading

Insider Buying: DNL insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUK£5,74007 Aug 19
Martin Whitaker
EntityIndividual
Role
Chief Executive Officer
CEO & Executive Director
Shares15,104
Max PriceUK£0.38
BuyUK£2,38024 Jun 19
Richard Bungay
EntityIndividual
Role
Member of the Board of Directors
CFO,Director & Company Secretary
Shares8,000
Max PriceUK£0.30

Ownership Breakdown


Management Team

  • Richard Bungay (50yo)

    CFO,Director & Company Secretary

    • Tenure: 2.8yrs
    • Compensation: UK£273.00k
  • Martin Whitaker

    CEO & Executive Director

    • Tenure: 0yrs
    • Compensation: UK£353.00k
  • Richard Ross

    Chief Scientific Officer & Executive Director

    • Tenure: 3.8yrs
    • Compensation: UK£35.00k
  • Michael Withe

    Commercial Director

    • Tenure: 0yrs
  • John Porter

    Medical Director

    • Tenure: 0yrs
  • Daniel Margetson

    Director of Chemistry

    • Tenure: 0yrs

Board Members

  • Richard Bungay (50yo)

    CFO,Director & Company Secretary

    • Tenure: 2.8yrs
    • Compensation: UK£273.00k
  • Alan Raymond

    Non-Executive Director

    • Tenure: 3.8yrs
    • Compensation: UK£29.00k
  • John Goddard (67yo)

    Independent Non-Executive Director

    • Tenure: 3.8yrs
    • Compensation: UK£15.00k
  • Peter Allen (63yo)

    Non Executive Chairman

    • Tenure: 0yrs
    • Compensation: UK£50.00k
  • Martin Whitaker

    CEO & Executive Director

    • Tenure: 0yrs
    • Compensation: UK£353.00k
  • Sam Williams (50yo)

    Non-Executive Director

    • Tenure: 3.8yrs
    • Compensation: UK£29.00k
  • Richard Ross

    Chief Scientific Officer & Executive Director

    • Tenure: 3.8yrs
    • Compensation: UK£35.00k

Company Information

Diurnal Group plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Diurnal Group plc
  • Ticker: DNL
  • Exchange: AIM
  • Founded: 2015
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£25.519m
  • Shares outstanding: 84.64m
  • Website: https://www.diurnal.co.uk

Number of Employees


Location

  • Diurnal Group plc
  • Cardiff MediCentre
  • Heath Park
  • Cardiff
  • South Glamorgan
  • CF14 4UJ
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
DNLAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPDec 2015

Biography

Diurnal Group plc operates as a specialty pharma company. The company develops hormone therapeutics for the treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insu ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 21:30
End of Day Share Price2019/10/14 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.